A detailed history of Black Rock Inc. transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 483,402 shares of SPRO stock, worth $570,414. This represents 0.0% of its overall portfolio holdings.

Number of Shares
483,402
Previous 476,896 1.36%
Holding current value
$570,414
Previous $820,000 23.41%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.27 - $1.8 $8,262 - $11,710
6,506 Added 1.36%
483,402 $628,000
Q1 2024

May 10, 2024

SELL
$1.35 - $1.79 $4,999 - $6,628
-3,703 Reduced 0.77%
476,896 $820,000
Q4 2023

Feb 13, 2024

SELL
$1.0 - $1.47 $1,210 - $1,778
-1,210 Reduced 0.25%
480,599 $706,000
Q3 2023

Nov 13, 2023

SELL
$1.2 - $1.63 $50,394 - $68,451
-41,995 Reduced 8.02%
481,809 $582,000
Q2 2023

Aug 11, 2023

BUY
$1.42 - $1.95 $48,267 - $66,282
33,991 Added 6.94%
523,804 $759,000
Q1 2023

May 12, 2023

BUY
$1.35 - $2.0 $2,335 - $3,460
1,730 Added 0.35%
489,813 $710,000
Q4 2022

Feb 13, 2023

SELL
$1.55 - $2.12 $316,285 - $432,596
-204,055 Reduced 29.48%
488,083 $844,000
Q3 2022

Nov 14, 2022

BUY
$0.68 - $2.2 $941 - $3,047
1,385 Added 0.2%
692,138 $1.39 Million
Q2 2022

Aug 12, 2022

SELL
$0.74 - $7.44 $816,462 - $8.21 Million
-1,103,328 Reduced 61.5%
690,753 $513,000
Q1 2022

May 12, 2022

SELL
$7.87 - $15.15 $36,957 - $71,144
-4,696 Reduced 0.26%
1,794,081 $15.6 Million
Q4 2021

Feb 10, 2022

SELL
$13.09 - $18.77 $49,100 - $70,406
-3,751 Reduced 0.21%
1,798,777 $28.8 Million
Q3 2021

Nov 09, 2021

BUY
$13.03 - $19.51 $308,889 - $462,504
23,706 Added 1.33%
1,802,528 $33.2 Million
Q2 2021

Aug 11, 2021

BUY
$12.22 - $15.79 $21.7 Million - $28.1 Million
1,778,822 New
1,778,822 $24.8 Million

Others Institutions Holding SPRO

About Spero Therapeutics, Inc.


  • Ticker SPRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,067,500
  • Market Cap $41.4M
  • Description
  • Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...
More about SPRO
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.